FDA approves Botox for migraine headaches

Oct 15, 2010 By MATTHEW PERRONE , AP Health Writer

(AP) -- Federal health officials approved the wrinkle-smoothing injection Botox for migraine headaches on Friday, giving drugmaker Allergan clearance to begin marketing its drug to patients with a serious history of the condition.

The approved the drug for patients who experience 15 or more days of headaches per month. Allergan, which specializes in beauty and eye-care drugs, said roughly 3.2 million people in the U.S. have chronic migraines.

For the new use, doctors are directed to inject patients in the neck or head every 12 weeks to dull future headaches.

Doctors currently use a wide variety of medications to treat migraines, ranging from over-the-counter like Advil to prescription narcotics like codeine. Many patients also respond to changes in diet or lifestyle, such as reducing caffeine or stress.

"This condition can greatly affect family, work and social life, so it is important to have a variety of effective treatment options available," said FDA's Dr. Russell Katz, director of neurology products, in a statement.

The FDA approved the new use based on two company studies of more than 1,300 patients who received either a Botox injection or a dummy injection. Patients who received Botox reported slightly fewer "headache days" than patients given the sham treatment. In the more significant of the two studies, patients on Botox reported about two fewer headache days than patients who didn't receive the drug.

Botox, which was introduced in 1989, is one of Allergan's top drugs, accounting or more than $1.3 billion of the company's $4.4 billion sales in 2009. The drug is most famous for its ability to smooth frown lines on aging foreheads, but it's also approved to treat neck spasms, eye muscle disorders and excessive underarm sweating.

The drug won approval earlier this year to treat spasms in the elbows, wrists and fingers. But it's also widely used off-label to treat broader movement disorders such as . works by blocking the connections between nerves and muscle, temporarily paralyzing the muscle. The drug is a purified form of botulinum, one of the most toxic substances in the world.

Explore further: FDA OKs Cubist antibiotic for serious infections

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Botox maker to pay $600M to resolve investigation

Sep 02, 2010

(AP) -- Allergan Inc., the maker of wrinkle-smoothing Botox, has agreed to pay $600 million to settle a yearslong federal investigation into its marketing of the top-selling, botulin-based drug.

Dysport the newest wrinkle-stopping drug to hit market

May 13, 2009

There's a new wrinkle remover on the market. Late last month, the U.S. Food and Drug Administration sanctioned Dysport for cosmetic and therapeutic use. Like Botox, it's an injectable drug derived from a botulinum toxin. ...

FDA warns of botulism with unapproved use of Botox

Apr 30, 2009

(AP) -- Health officials warned doctors and patients Thursday about potentially deadly risks of using the anti-wrinkle drug Botox and similar drugs for unapproved uses to treat certain types of muscle spasms.

Botox eases nerve pain in certain patients

Jun 10, 2010

Made popular for its ability to smooth wrinkles when injected into the face, Botox — a toxin known to weaken or paralyze certain nerves and muscles — may have another use that goes beyond the cosmetic.

Botox reduces wrinkles even in less frequent doses

Apr 26, 2010

Patients can decrease the frequency of Botox Cosmetic injections after approximately two years and still receive most of the same wrinkle-smoothing cosmetic benefits, according to new research at Oregon Health & Science University.

FDA approves first drug for infantile spasms

Aug 21, 2009

(AP) -- The Food and Drug Administration has approved the first drug to treat infantile spasms, a rare disorder that can cause hundreds of seizures per day in children less than a year old.

Recommended for you

FDA OKs Cubist antibiotic for serious infections

Dec 20, 2014

The Food and Drug Administration has approved a new medicine to fight complex infections in the abdomen and urinary tract, the fourth antibiotic the agency has approved since May.

Xtoro approved for swimmer's ear

Dec 18, 2014

(HealthDay)—Xtoro (finafloxacin otic suspension) eardrops have been approved by the U.S. Food and Drug Administration to treat swimmer's ear, clinically known as acute otitis externa.

Drug interaction identified for ondansetron, tramadol

Dec 18, 2014

(HealthDay)—In the early postoperative period, ondansetron is associated with increased requirements for tramadol consumption, according to a review and meta-analysis published online Dec. 10 in Anaesthesia.

New system targets germs in donated blood plasma

Dec 17, 2014

(HealthDay)—A new system designed to eliminate germs in donated blood plasma and reduce the risk of transmitting a plasma-borne infection has been approved by the U.S. Food and Drug Administration.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.